IQVIA’s Orchestrated Customer Engagement (OCE) Solution Adopted by More than 30 Life Sciences Companies in First Year of Launch
IQVIA™ (NYSE:IQV) today announced that more than 30 life sciences companies have selected Orchestrated Customer Engagement (OCE) as their commercial solution in the 12 months since the groundbreaking technology first launched. OCE customers include top-20 global pharmaceutical companies, Novo Nordisk and Roche, as well as Adhera Therapeutics, Napo Pharmaceuticals, Pierre Fabre Pharmaceuticals, PruGen Pharmaceuticals, Recordati, and Theramex. IQVIA launched the new category of cloud-based life sciences technology on December 12, 2017 - today, OCE is live in 115 countries.
This milestone validates the need within the market for more sophisticated customer engagement, a need that’s met by OCE’s innovative solution and the orchestrated commercial model. It also reflects the value of IQVIA’s platform-of-platforms strategy, exemplified by our long-term and expanding alliance with Salesforce to build transformative life science applications across the product lifecycle.
IQVIA Technologies’ OCE empowers life sciences companies to evolve their commercial models away from organizational silos. With OCE, companies can take an integrated approach that coordinates customer-facing roles to operate as a team, connect all human and digital touchpoints and create an exceptional, personalized experience. While applying artificial intelligence and intuitive user interfaces, the OCE platform reduces friction, enhances productivity, increases value, and enables better decision-making across the enterprise, while integrating seamlessly with other IQVIA solutions such as CRM and Master Data Management.
“The out-of-the-gate adoption of OCE proves that IQVIA has its finger on the pulse of the market’s technology needs,” said Tal Rosenberg, senior vice president, Global Technology Solutions for IQVIA. “We will continue to develop and deliver innovative technologies to help our customers and HCPs engage more productively and make better decisions.”
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With more than 55,000 employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing the information that helps their customers drive human health outcomes forward. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190107005336/en/